Bevacizumab in the therapy for refractory metastatic colorectal cancer

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Colorectal cancer is the second most common cause of cancer related deaths in the United States. Recent developments have led to prolonged survival with the use of sequential lines of chemotherapy agents. The addition of bevacizumab to active chemotherapy has further improved survival when used in the fi rst and second lines of therapy for metastatic colorectal cancer. Evidence supporting the continued use of bevacizumab throughout lines of therapy is accumulating. Clinical trials are underway in which bevacizumab is continued beyond the fi rst line of a chemotherapy and bevacizumab combination regimen. The mechanism by which colorectal cancer may become resistant to bevacizumab is poorly understood. Molecular and biochemical correlates which may identify bevacizumab resistance are an important component in the design of these clinical trials.

Original languageEnglish (US)
Pages (from-to)53-60
Number of pages8
JournalBiologics: Targets and Therapy
Issue number1
StatePublished - 2008


  • Bevacizumab
  • Colorectal cancer
  • Refractory

ASJC Scopus subject areas

  • Gastroenterology
  • Pharmacology (medical)
  • Oncology
  • Immunology and Allergy
  • Rheumatology


Dive into the research topics of 'Bevacizumab in the therapy for refractory metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this